To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL LIMITED - Trading statement Audited group results for the year ended 31 March 2013

Release Date: 17/05/2013 09:00
Code(s): MDC     PDF:  
Wrap Text
Trading statement – Audited group results for the year ended 31 March 2013

MEDICLINIC INTERNATIONAL LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 1983/010725/06)
(Share code: MDC)
(ISIN: ZAE000074142)
("Mediclinic" or “the Company”)

TRADING STATEMENT – AUDITED GROUP RESULTS FOR THE YEAR ENDED
31 MARCH 2013

In terms of the JSE Limited (“JSE”) Listings Requirements,
companies are required to publish a trading statement as soon as
they are satisfied that a reasonable degree of certainty exists
that the financial results for the period to be reported upon next
will differ by at least 20% from that of the previous
corresponding reporting period. Mediclinic is in the process of
finalising its year-end results for the twelve months ended 31
March 2013, which are due to be released on SENS on 22 May 2013
and published in the press on 23 May 2013 (“year-end results
announcement”).

Accordingly, shareholders are advised that the Company’s basic
earnings per share (“EPS”) and basic headline earnings per share
(“HEPS”) for the year ended 31 March 2013 are expected to be
between 164% and 174% lower than that reported for the previous
corresponding reporting period (“the EPS and HEPS range”).

In order to provide clear and meaningful guidance to shareholders,
this trading statement will also address normalised HEPS.
Normalised HEPS are defined as reportable HEPS in terms of
accounting standards, excluding one-off items.

The one-off items are included in calculating the EPS and HEPS
range and relate mainly to the refinancing charges as reported in
the interim results on 6 November 2012. Details of one-off items
will be provided in the year-end results announcement. Excluding
the one-off items, the normalised HEPS for the year ended 31 March
2013 are expected to be between 37% and 47% higher than the
normalised HEPS reported for the previous corresponding reporting
period.

The financial information on which this trading statement is based
has not been reviewed and reported on by the Company’s external
auditors.

Stellenbosch
17 May 2013

Mediclinic Offices, Strand Road, Stellenbosch 7600, South Africa
PO Box 456, Stellenbosch 7599, South Africa
Tel +27 21 809 6500
Fax +27 21 886 4037
Ethics line: 0800 005 316
Website: www.mediclinic.com

Sponsor
RAND MERCHANT BANK (A division of FirstRand Bank Limited)

Date: 17/05/2013 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story